Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.50 |
| ▸ | ATR | Q13535 | 13/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729100 | 0.89 | CYP4F2 (0.47) | CYP4F2CYP4A11ATRIDH1 | |
| SCHEMBL20641888 | 0.87 | CYP4F2 (0.46) | CYP4F2CYP4A11ATRIDH1 | |
| SCHEMBL21724972 | 0.86 | CYP4F2 (0.50) | CYP4F2CYP4A11ATRIDH1NR3C2 | |
| SCHEMBL23154226 | 0.85 | ATR (0.49) | CYP4F2CYP4A11ATRIDH1 | |
| SCHEMBL12079810 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11ATRIDH1 | |
| SCHEMBL1817328 | 0.80 | ATR (0.50) | CYP4F2CYP4A11ATRIDH1 | |
| SCHEMBL12092426 | 0.79 | CYP4F2 (0.52) | CYP4F2CYP4A11ATR | |
| SCHEMBL29653668 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11ATR | |
| SCHEMBL23500594 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11ATR | |
| SCHEMBL2685154 | 0.79 | CYP4F2 (0.51) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | CYP4F2 271/4885CYP4A11 273/4885ATR 725/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | CYP4F2 271/4885CYP4A11 273/4885ATR 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.